Thrivent Financial for Lutherans Purchases 45,516 Shares of ANI Pharmaceuticals, Inc. $ANIP

Thrivent Financial for Lutherans lifted its position in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 363.8% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 58,027 shares of the specialty pharmaceutical company’s stock after acquiring an additional 45,516 shares during the period. Thrivent Financial for Lutherans’ holdings in ANI Pharmaceuticals were worth $5,315,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also added to or reduced their stakes in the company. Advisors Asset Management Inc. acquired a new position in ANI Pharmaceuticals during the first quarter valued at approximately $28,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of ANI Pharmaceuticals by 4.5% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 10,993 shares of the specialty pharmaceutical company’s stock worth $736,000 after buying an additional 470 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in shares of ANI Pharmaceuticals by 0.9% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 48,322 shares of the specialty pharmaceutical company’s stock worth $3,235,000 after buying an additional 423 shares during the last quarter. Jane Street Group LLC acquired a new stake in ANI Pharmaceuticals in the first quarter valued at about $2,706,000. Finally, KLP Kapitalforvaltning AS grew its position in ANI Pharmaceuticals by 23.3% in the second quarter. KLP Kapitalforvaltning AS now owns 3,700 shares of the specialty pharmaceutical company’s stock valued at $241,000 after acquiring an additional 700 shares during the last quarter. 76.05% of the stock is owned by institutional investors.

ANI Pharmaceuticals Stock Up 0.4%

NASDAQ:ANIP opened at $81.84 on Friday. ANI Pharmaceuticals, Inc. has a one year low of $54.10 and a one year high of $99.50. The company has a debt-to-equity ratio of 1.20, a current ratio of 2.58 and a quick ratio of 2.04. The company has a market cap of $1.84 billion, a PE ratio of 50.21 and a beta of 0.50. The firm’s 50 day simple moving average is $81.64 and its 200 day simple moving average is $85.46.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its quarterly earnings results on Friday, November 7th. The specialty pharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.74 by $0.30. The firm had revenue of $227.81 million during the quarter, compared to the consensus estimate of $211.92 million. ANI Pharmaceuticals had a net margin of 4.91% and a return on equity of 26.73%. The company’s revenue for the quarter was up 53.6% on a year-over-year basis. During the same quarter last year, the firm earned $1.34 earnings per share. On average, research analysts anticipate that ANI Pharmaceuticals, Inc. will post 3.86 earnings per share for the current year.

Insiders Place Their Bets

In related news, Director Patrick D. Walsh sold 8,643 shares of the firm’s stock in a transaction on Thursday, November 13th. The stock was sold at an average price of $86.88, for a total transaction of $750,903.84. Following the completion of the transaction, the director directly owned 61,405 shares of the company’s stock, valued at $5,334,866.40. This trade represents a 12.34% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Meredith Cook sold 500 shares of ANI Pharmaceuticals stock in a transaction dated Tuesday, January 13th. The stock was sold at an average price of $84.33, for a total value of $42,165.00. Following the transaction, the vice president directly owned 74,374 shares in the company, valued at $6,271,959.42. The trade was a 0.67% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 28,101 shares of company stock valued at $2,453,063 over the last ninety days. 11.10% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

ANIP has been the subject of a number of research reports. Barclays assumed coverage on shares of ANI Pharmaceuticals in a report on Tuesday, December 9th. They issued an “overweight” rating and a $100.00 target price for the company. Weiss Ratings reissued a “hold (c+)” rating on shares of ANI Pharmaceuticals in a research note on Monday, December 29th. Guggenheim raised their target price on shares of ANI Pharmaceuticals from $115.00 to $124.00 and gave the company a “buy” rating in a research report on Friday, January 16th. Finally, Zacks Research downgraded shares of ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, January 6th. Six research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat, ANI Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $103.43.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.